BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its stake in shares of Celgene Corporation (NASDAQ:CELG) by 0.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 529,992 shares of the biopharmaceutical company’s stock after selling 2,418 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned approximately 0.07% of Celgene Corporation worth $68,830,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in CELG. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation in the first quarter valued at approximately $118,000. Acropolis Investment Management LLC acquired a new position in shares of Celgene Corporation in the second quarter valued at approximately $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 380 shares in the last quarter. Rational Advisors LLC acquired a new position in shares of Celgene Corporation in the second quarter valued at approximately $156,000. Finally, Oakworth Capital Inc. grew its holdings in shares of Celgene Corporation by 11.7% in the second quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 127 shares in the last quarter. Institutional investors and hedge funds own 79.36% of the company’s stock.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock worth $6,268,259 over the last quarter. 0.95% of the stock is currently owned by company insiders.

WARNING: “Celgene Corporation (CELG) Holdings Decreased by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/celgene-corporation-celg-holdings-decreased-by-british-columbia-investment-management-corp/1631729.html.

CELG has been the subject of a number of research reports. Vetr cut shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective for the company. in a report on Tuesday, August 29th. Cantor Fitzgerald restated a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. Bank of America Corporation restated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, September 13th. Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and lifted their price objective for the company from $96.93 to $160.00 in a report on Monday, July 31st. Finally, Jefferies Group LLC restated a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and twenty-two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $150.80.

Celgene Corporation (NASDAQ CELG) opened at 136.46 on Friday. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $147.17. The firm has a 50-day moving average of $141.03 and a 200 day moving average of $130.11. The firm has a market capitalization of $106.76 billion, a PE ratio of 42.26 and a beta of 1.88.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same period last year, the business posted $1.44 earnings per share. Analysts predict that Celgene Corporation will post $7.33 earnings per share for the current year.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.